GlassScriptPhysician profile
Alan M Sanders
NPI 1063478691
$6,820.97
in general payments reported to CMS, 2019-2025
33 companies · $1,140 in 2025
The $1,140 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $629 · 2020: $1,075 · 2021: $1,239 · 2022: $794 · 2023: $844 · 2024: $1,100 · 2025: $1,140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,064 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,064.08 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,079.47 | 2019-2025 | Jardiance, Ofev, Spiriva Respimat |
| Amgen INC. | $721.69 | 2019-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $649.90 | 2019-2025 | Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $542.77 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $492.67 | 2019-2025 | Farxiga, Airsupra |
| Lilly USA, LLC | $485.92 | 2019-2025 | Jardiance, Mounjaro |
| Sanofi-Aventis U.S. LLC | $403.37 | 2019-2023 | |
| Pfizer INC. | $341.84 | 2019-2025 | |
| Glaxosmithkline, LLC. | $332.74 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Abbvie INC. | $271.01 | 2021-2025 | Vraylar, Ubrelvy, Synthroid |
| Corcept Therapeutics | $231.83 | 2024-2025 | Korlym |
| Novartis Pharmaceuticals Corporation | $206.89 | 2019-2025 | |
| Eisai INC. | $173.98 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $128.95 | 2019-2024 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $106.15 | 2022-2025 | Xifaxan |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $93.96 | 2019-2023 | Belsomra |
| Otsuka America Pharmaceutical, INC. | $90.00 | 2024-2025 | Rexulti |
| Amarin Pharma, INC. | $70.55 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.54 | 2021 | |
| Esperion Therapeutics, INC. | $41.77 | 2021-2024 | Nexletol |
| E.R. Squibb & Sons, L.L.C. | $41.71 | 2022-2024 | Eliquis, Camzyos |
| Edwards Lifesciences Corporation | $38.16 | 2025 | Sapien 3 Ultra Resilia |
| Daiichi Sankyo INC. | $35.59 | 2021-2023 | Injectafer |
| Verona Pharma, INC. | $35.00 | 2025 | Ohtuvayre |
| Inspire Medical Systems, INC. | $25.66 | 2025 | Inspire |
| Abbott Laboratories | $23.18 | 2025 | Freestyle Libre 3 |
| Shire North American Group INC | $18.81 | 2019 | |
| Dexcom, INC. | $16.81 | 2023 | Dexcom G6 Transmitter |
| Idorsia Pharmaceuticals US INC | $16.79 | 2023 | Quviviq |
| Boston Scientific Corporation | $16.08 | 2025 | Watchman Access System |
| Athena Bioscience, LLC | $14.76 | 2024 | Qdolo |
| Paratek Pharmaceuticals, INC. | $14.55 | 2020 | |
| Phathom Pharmaceuticals, INC. | $13.87 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Sanders listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.